Skip to main content
OpenTrials
Completed

NCT Number: NCT02935296

Integrated Treatment and Prevention for People Who Inject Drugs

The purpose of this study is to determine the feasibility of a future trial that will assess whether an integrated intervention combining psychosocial counseling and supported referrals for antiretroviral therapy (ART) at any CD4 cell count and substance use treatment for HIV-infected people who inject drugs (PWID) will reduce HIV transmission to HIV-uninfected injection partners, as compared to routine care dictated by national guidelines for HIV-infected PWID.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–45 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

CIPTO, Jakarta, Indonesia

Loading trial locations.

About this study

This is a multi-site, two-arm, randomized, vanguard study. Network units will consist of an HIV-infected index participant and his/her HIV-uninfected network injection partner(s). Network units will be randomized to the intervention or standard of care arms in a 1:3 ratio, stratified by site. To assess feasibility of the intervention, additional interviews will be conducted with study staff (systems navigators and counselors) and clinic-based stakeholders at each study site.

Approximately 500 Index participants and their partners will be enrolled.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Index participants:

  • Age 18-45 years at the Screening visit (age verification procedures will be defined in the Study Specific Procedures [SSP] Manual)
  • Able to provide informed consent
  • Active injection drug user, defined as self-report of: a) injecting drugs approximately two or more times per week for the past three months, and b) ability to identify the anatomical location of the most recent injection site, as determined by study staff
  • Reports sharing needles/syringes or drug solutions at least once in the last month
  • HIV-infected based on a study-defined testing algorithm (defined in the SSP Manual)
  • Viral load ≥1,000 copies/mL at Screening
  • Willing and able to identify, recruit, and have enrolled at least one HIV-uninfected network injection partner who is eligible for study participation according to the criteria below
  • Have no plans to move outside the study area for at least one year after study enrollment
  • Willing to participate in intervention activities, including regular phone contact

HIV uninfected injection partners:

  • Age 18-45 years at the Screening visit (age verification procedures will be defined in the SSP Manual)
  • Able to provide informed consent
  • Active injection drug user, defined as: a) self-report of injecting drugs approximately two times per week for the past three months, and b) ability to identify the anatomical location of the most recent injection site, as determined by study staff
  • Confirmed injection partner, using referral identification cards, of index participant within the past 1 month
  • HIV-uninfected based on the study-defined testing algorithm* (defined in the Study SSP Manual)
  • Have no plans to move outside the study area for at least one year after study enrollment

Exclusion criteria

-

Treatment and study plan

Integrated Intervention

Behavioral

systems navigation, psychosocial counseling

Primary outcomes

  1. HIV incidence among network injection partners of index participants

    Time frame: 18 months

    Number of HIV seroconversions to partners to control arm Index participants

  2. enrollment and retention of HIV-infected PWID and their HIV-uninfected network injection partners

    Time frame: 18 months

    Number of participants enrolled, and number of participants with a final study visit.

Secondary outcomes

  1. HIV incidence among network injection partners of index participants in the intervention arm

    Time frame: 18 months

    Number of HIV seroconversions to partners of Intervention arm participants

  2. Engagement in care for ART treatment services of control arm vs intervention

    Time frame: 18 months

    Number of participants in both arms who report being in ART (case report forms) care, as well as testing stored plasma for HIV RNA suppression

  3. Number of participants in either arm engaged in substance use treatment

    Time frame: 18 months

    self reported on case report forms

  4. size and stability of drug using networks

    Time frame: 18 months

    self reported data via questionnaire of drug sharing habits and partners at each study visit

  5. social harms and benefits

    Time frame: 18 months

    self report via questionnaire

  6. phylogenetics to describe HIV transmission dynamics

    Time frame: 18 months

    stored plasma samples from those persons who are HIV positive and those who become HIV positive during the study

Sponsors and collaborators

Lead sponsor

HIV Prevention Trials Network

Network

Collaborators

  • National Institute of Allergy and Infectious Diseases (NIAID)
  • National Institute on Drug Abuse (NIDA)

Registry information

Official study title

Integrated Treatment and Prevention for People Who Inject Drugs: A Vanguard Study for a Network-based Randomized HIV Prevention Trial Comparing an Integrated Intervention Including Supported Antiretroviral Therapy to the Standard of Care

Important dates

Study start
2015
Primary completion
2017
Study completion
2018
First posted
Oct 17, 2016
Registry last updated
Apr 1, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.